Saskia Litière, Biostatistician at the EORTC, discusses the ongoing evaluation of RECIST with Helen Saul
10 Feb 2015
Hear Saskia Litière, EORTC Biostatistician, discuss “The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumors 1.1 database”, an article published in European Journal of Cancer (2015) 51, 1847-1853.
Related News
PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases
27 Feb 2026
EORTC celebrates Rare Disease Day: Addressing unmet needs in rare cancers
27 Feb 2026
First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma
26 Feb 2026
World Cancer Day: How clinical cancer research changes lives
4 Feb 2026
New international study shows access to patient-reported outcome data improves the consistency of the evaluation of cancer treatment adverse events
27 Jan 2026
First Site Activated and First Patient Randomised in new brain cancer study VIGOR – EORTC‑2427‑BTG
26 Jan 2026
EORTC and EMA, jointly with international stakeholders, have published a multistakeholder roadmap to accelerate treatment optimisation in oncology
16 Jan 2026
New EORTC quality of life questionnaire for adolescents and young adults with cancer
8 Jan 2026
P-Value Workshop
19 Dec 2025
EORTC participation at ISPOR Europe 2025 conference
7 Nov 2025
